1. China Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
Luyan Pharma Co., Ltd. Class A

Luyan Pharma Co., Ltd. Class A

SSZSE:002788
9.76
CNY
+0.08
(+0.83%)
0.73EPS
13.65P/E
3.90BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.04
23.99
25.16
20.97
23.79
32.67
42.82
43.12
45.32
50.18
51.32
52.71
54.46
54.18
Basic EPS, GAAP
0.41
0.42
0.43
0.35
0.37
0.51
0.73
0.74
0.79
0.89
0.94
0.89
0.72
0.73
Free Cash Flow per Basic Share
-0.82
0.35
-0.16
-0.72
-1.51
-0.02
-2.36
-0.31
-1.59
-0.25
2.02
0.56
1.17
- -
Dividend per Share
0.22
0.36
0.36
0.27
0.28
0.41
0.53
0.59
0.65
0.85
0.88
0.83
0.8
0.44
Book Value per Share
2.1
2.44
2.8
3.9
4.2
4.47
5.1
6.13
6.41
7
7.58
8.14
8.51
8.53
Tangible Book Value per Share
1.84
2.07
2.44
3.65
3.63
3.34
3.91
5.11
5.24
5.8
5.93
6.47
6.85
6.85
Basic Weighted Avg Shares
262
263
263
333
351
352
351
360
387
388
387
388
390
391
Sales/Revenue/Turnover
5,520
6,300
6,626
6,983
8,338
11,501
15,009
15,535
17,545
19,463
19,846
20,471
21,247
21,200
Operating Margin (%)
3.87
3.72
3.69
3.3
3.38
3.43
3.55
3.78
3.64
3.83
3.63
3.38
2.81
2.79
Depreciation Expense
11
17
20
22
26
35
42
48
113
113
121
131
137
- -
Net Income, GAAP
108
109
113
116
131
180
256
267
306
345
364
346
281
287
Effective Tax Rate (%)
25.91
26.94
26.01
25.82
27.68
28.94
25.16
28.1
26.64
24.69
22.35
23.29
25.85
26.75
Profit Margin (%)
1.96
1.74
1.71
1.65
1.57
1.57
1.7
1.72
1.74
1.77
1.83
1.69
1.32
1.36
Working Capital
203
230
325
875
885
768
784
1,235
1,307
1,447
1,292
1,265
875
968
LT Debt
14
14
17
16
49
120
117
183
264
526
653
736
409
501
Total Equity
558
649
746
1,378
1,566
1,654
1,888
2,447
2,560
2,791
2,977
3,192
3,324
3,327
Return on Invested Capital (%)
8.57
6.49
6.09
5.42
5.05
5.06
5.69
4.78
4.54
4.73
4.66
4.43
3.46
3.32
Return on Capital (%)
12.21
10.03
9.22
7.6
6.05
7.15
8.08
6.85
6.75
6.78
6.84
6.3
5.08
4.89
Return on Common Equity (%)
21.67
18.28
16.45
10.96
9.18
11.85
15.23
12.78
12.55
13.24
12.83
11.32
8.68
8.78

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,480
4,773
4,777
LT Borrowings
327
383
429
LT Finance Leases
82
81
72
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
389
389
389
Market Capitalization
8,229
6,282
3,897

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
10,458
10,416
10,258
Cash, Cash Equivalents & STI
617
556
649
Accounts Receivable, Net
6,363
6,514
6,187
Inventories
3,035
2,851
2,931
Total Current Liabilities
9,582
9,411
9,290
Payables & Accruals
- -
- -
- -
ST Debt
4,480
4,773
4,777
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.94%
6.33%
4.14%
Free Cash Flow
1,143.75%
-101.27%
110.14%
Net Income, GAAP
10.82%
1.84%
-18.74%
Sales/Revenue/Turnover
12.95%
6.56%
3.79%
Total Cash Common Dividend
13.84%
8.92%
-3.05%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,136
5,170
5,107
5,057
20,471
2025
5,174
5,226
- -
5,391
21,247
2026
5,351
5,232
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.27
0.17
0.23
0.89
2025
0.18
0.21
- -
0.16
0.72
2026
0.17
0.19
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.13
0.43
0.16
0.83
2025
0.11
0.11
- -
0.13
0.8
2026
0.11
0.09
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jin Xiang Wu
Full Time Employees
5,722
Sector
Retail trade
Industry
Drugstore chains
Address
No. 1004, Anling Road Xiamen FU China 361015
IPO Date
Feb 18, 2016
Website
luyan.com.cn
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
TSURUHA Holdings, Inc. (TSE:3391)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
Luyan Pharma Co., Ltd. (002788.SZ) is a China-based pharmaceutical company principally engaged in the distribution and retail of medicines, Chinese herbal medicines, medical devices, vaccines, and related products; it also operates pharmaceutical retail chains, provides medical care, elderly care, and wellness services, and pursues research, development, production, and sale of pharmaceutical products. Founded in 1992 and headquartered in Xiamen, China, the company primarily targets medical institutions across Fujian Province while expanding operations to regions including Jiangxi, Sichuan, and Hainan through subsidiaries and retail networks such as Luyan (Fujian), Jiangxi Luyan, and Sichuan Luyan outlets. Its business segments encompass medicine wholesale (accounting for the majority of sales), pharmaceutical retail, pharmaceutical manufacturing, and other services, with a focus on human health solutions delivered directly to hospitals and consumers. Formerly known as Luyan (Fujian) Pharma Co., Ltd., the company changed its name to Luyan Pharma Co., Ltd. in June 2016 following its listing on the Shenzhen Stock Exchange on February 18, 2016; it continues to grow its pharmaceutical industry segment, which saw revenues rise to CNY618 million in 2024 from CNY367 million in 2022. Recent developments include earning three industry awards in September 2025 for leadership in sector advancement, hosting strategic visits from Fujian officials and universities in mid-2025 to explore collaborations, and conducting anti-commercial bribery training in June 2025 amid ongoing expansion of its retail pharmacy footprint.